2026-04-05 · Consumer-facing US drug shortage intelligence — real-time shortage dashboards, manufacturer accountability scorecards, duration timelines, alternative-drug guidance, therapeutic-area impact analysis, and weekly "shortage dispatch" briefings, all auto-generated from FDA's openAPI and delivered as a beautiful, opinionated, patient-first static site.

Dry Spell

Your prescription vanished. We track who ran out, who's responsible, and what you can do about it.

💡 idea Total 16/20 Quality 5 Automation 4 Revenue 3 Complexity 4

Channel: Dry Spell Tagline: Your prescription vanished. We track who ran out, who’s responsible, and what you can do about it. Niche: Consumer-facing US drug shortage intelligence — real-time shortage dashboards, manufacturer accountability scorecards, duration timelines, alternative-drug guidance, therapeutic-area impact analysis, and weekly “shortage dispatch” briefings, all auto-generated from FDA’s openAPI and delivered as a beautiful, opinionated, patient-first static site. Target audience: The 130+ million Americans who take at least one prescription drug. Specifically: patients who’ve walked into a pharmacy and been told “we don’t have it” (estimated 15-20 million people affected by shortages annually), caregivers managing complex medication regimens, pharmacists looking for a patient-friendly resource to share, health journalists covering the crisis, patient advocacy organizations, and the massive ADHD community (10M+ US adults) currently experiencing the longest stimulant shortage in history. Why now: Drug shortages in the US have hit crisis levels. The FDA currently tracks 1,693 shortage entries in its database. ADHD medications (Vyvanse, Adderall) have been in continuous shortage since late 2022 — over 3 years now. Chemotherapy drugs like Carboplatin have been rationed in cancer centers. Hospital-essential IV fluids (dextrose, saline) face chronic unavailability. The 2024 ASHP survey found 99% of hospitals experienced at least one drug shortage. Yet the consumer experience of this crisis is: walking into CVS, being told “try back next week,” and Googling into a void. The FDA’s own shortage page is an unusable wall of text with no visualizations, no trend data, and no patient guidance. Nobody owns this beat as a continuously-updated, beautifully-designed data product. The gap is enormous.

Content Example:

Sample Article: “The Adderall Drought Hits 1,200 Days — And Teva Still Won’t Say Why”

Published: Dry Spell Weekly Dispatch #47

The number: 1,200 days. That’s how long mixed amphetamine salts (the generic name for Adderall) have been in continuous shortage in the United States — the longest stimulant supply disruption since the DEA began regulating production quotas in 1971.

If you’re one of the ~10 million American adults with an ADHD prescription, you already know this. You’ve called six pharmacies on a Tuesday morning. You’ve driven 40 miles to a Walgreens that “might have some.” You’ve spent $380 out-of-pocket for a 30-day supply of brand-name Vyvanse because the generic was gone. You’ve rationed your own medication — taking half doses, skipping weekends — and then watched your productivity, relationships, and mental health deteriorate.

But here’s what you probably don’t know: who’s responsible, and why it hasn’t been fixed.

The Manufacturer Scorecard

Dry Spell tracks every FDA shortage entry for amphetamine salts since 2022. Here’s our accountability breakdown:

ManufacturerEntriesAvg. Days ShortCurrent StatusReliability Grade
Teva Pharmaceuticals18340⚠️ LimitedD
Sandoz (Novartis)12280✅ AvailableC+
Lannett Company9410❌ UnavailableF
Mallinckrodt7195⚠️ LimitedC

Teva controls approximately 30% of the US generic Adderall market. They’ve filed 18 separate shortage notifications with the FDA since the crisis began — more than any other manufacturer. Their stated reason, consistently, is “increased demand.” But DEA production quota data tells a different story: quotas have been raised three times since 2023. The raw material isn’t scarce. The manufacturing capacity is.

Why “Increased Demand” Isn’t the Real Answer

The FDA’s openFDA database reveals a pattern: 87% of stimulant shortage entries cite “increased demand” or “demand increase” as the reason. But when you cross-reference with DEA quota data and manufacturer quarterly earnings calls:

The real story isn’t demand. It’s that manufacturing-quality failures at key facilities (see: FDA Warning Letter to Lannett’s Seymour, IN plant, June 2024) cascaded through a supply chain that had no redundancy, while surviving manufacturers discovered that scarcity is profitable.

What You Can Do Right Now

Check availability: Use Dry Spell’s live tracker (updated daily from FDA data) to see which specific NDC codes are available from which manufacturers.

Alternative medications currently NOT in shortage:

Talk to your doctor about: dose-form switching (XR ↔ IR availability differs), authorized generics (sometimes available when regular generics aren’t), and 90-day fills when stock appears.

Data sources: openFDA Drug Shortages API (last sync: 2026-04-05), FDA FAERS, DEA ARCOS quota data

Data Sources:

Automation Pipeline:

Tech Stack:

Monetization Model:

Growth Mechanics:

Channel Soul & Personality

Name: Dry Spell — a drought metaphor for when your medicine supply dries up. Memorable, slightly dark humor, immediately understood.

Mascot: A grumpy, world-weary pharmacy pill bottle character named Script — cracked, half-empty, wearing a hard hat. Drawn in a clean editorial illustration style (think New Yorker meets infographic). Script appears in article headers, delivers snarky commentary, and appears on the 404 page holding a “BACK-ORDERED” sign.

Voice: The exhausted but furious patient advocate who happens to have a data science degree. Not neutral. Not “both sides.” Takes the patient’s side, names manufacturers, demands accountability — but backs everything with data. Think ProPublica meets an angry pharmacist’s blog.

Signature phrases:

Running segments:

Visual style: Clean, medical-white backgrounds. Data visualizations in a distinctive teal + coral palette. Drug molecule diagrams as decorative elements. Pill bottle iconography throughout. Typography: clean sans-serif (Inter) for body, editorial serif (Source Serif) for headlines.

The opinion: Dry Spell believes drug shortages are a predictable result of market consolidation, regulatory inertia, and perverse incentives — not inevitable natural disasters. The channel takes the position that transparency is the first step to fixing a broken supply chain. Every manufacturer gets a grade. Every excuse gets fact-checked.

Launch Complexity: 3/5 (API is straightforward and well-documented; main complexity is designing the drug page template and manufacturer scoring algorithm; 2-3 weeks to MVP) Content Quality Score: 5/5 (genuinely life-affecting information that doesn’t exist in this form; sample article demonstrates investigative quality) Automation Score: 5/5 (FDA API updates daily with structured data; comparison/delta detection is straightforward; drug pages auto-generate from templates) Revenue Potential: 5/5 (massive affected audience, high emotional investment, clear path to newsletter monetization + affiliate revenue + becoming authoritative source) Total: 18/20

Why This Will Work: Psychology: When your medication disappears, the emotional response is fear, frustration, and helplessness. Dry Spell converts helplessness into information and agency. “I can’t get my Adderall” becomes “Here’s exactly why, here’s who’s responsible, here’s what to do.” That transformation — from anxious Googling to informed action — creates intense loyalty and willingness to donate/subscribe.

Market logic: 130M+ Americans take prescription drugs. 15-20M are affected by shortages annually. The ADHD community alone (10M+ adults) has been in crisis for 3+ years with no dedicated resource. Reddit threads about drug shortages get thousands of upvotes. The data is free, the audience is massive, and the competition is a government webpage from 2004.

Risk & Mitigation: